Patent ID: 11919965
Assignee: REGENERON PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method of treating multiple myeloma in a human subject in need thereof, the method comprising administering to the subject a bispecific antibody comprising a first heavy chain paired with a common light chain comprising a first antigen-binding domain that specifically binds a human B-cell maturation antigen (BCMA), and a second heavy chain paired with a common light chain comprising a second antigen-binding domain that specifically binds human CD3, wherein the first heavy chain comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 66 and a human IgG heavy chain constant region, the second heavy chain comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 90 and a human IgG heavy chain constant region, and the common light chain comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 82 and a human light chain constant region,
wherein the bispecific antibody is administered to the subject in a dosing regimen comprising: (a) administration of a single dose of 5 mg of the bispecific antibody during week one of the dosing regimen; (b) administration of a single dose of 25 mg of the bispecific antibody during week two of the dosing regimen; and (c) administration of a single dose of 200 mg of the bispecific antibody during week three of the dosing regimen.